Class act: Safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma

Mauricio Burotto, Syed Abbas Ali, Geraldine O'sullivan Coyne

Research output: Contribution to journalReview article

Abstract

Introduction: The past decade has seen the development and widespread use of tyrosine kinase inhibitors (TKIs) targeting a mutated EGFR (mEGFR) for the treatment of metastatic NSCLC. We discuss the main properties of the TKIs currently recommended for the treatment of mEGFR NSCLC: gefitinib, erlotinib and afatinib.Areas covered: The mechanism of action, pharmacodynamics and pharmacokinetics of these drugs, with emphasis on the historical context of their preclinical and clinical development, will be covered, including potential resistance mechanisms to these first-generation TKIs that has driven the trial design for second and third generations of EGFR inhibitors. Six Phase III clinical trials comparing these three TKIs with cisplatin-based chemotherapy upfront for mEGFR NSCLC provide the basis for the comparative safety and toxicity analysis between these agents. Class-related toxicity of these EGFR inhibitors, including life-threatening effects, will be discussed.Expert opinion: Toxicity and safety analysis from the Phase III trials of these agents in mEGFR populations suggests that afatinib has more frequent and severe side effects. Given that an efficacy advantage has not yet been demonstrated for afatinib over erlotinib and gefitinib, the consistent class toxicity profile of these agents means that gefitinib and erlotinib are a safer first-line treatment recommendation.

Original languageEnglish (US)
Pages (from-to)97-110
Number of pages14
JournalExpert Opinion on Drug Safety
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Safety
Phase III Clinical Trials
Expert Testimony
Cisplatin
Therapeutics
Pharmacokinetics
Drug Therapy
Pharmaceutical Preparations
Population
gefitinib
BIBW 2992
Erlotinib Hydrochloride

Keywords

  • Afatinib
  • Clinical trial
  • Erlotinib
  • Gefitinib
  • Mutated EGFR
  • Safety
  • Toxicity
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Class act : Safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma. / Burotto, Mauricio; Ali, Syed Abbas; O'sullivan Coyne, Geraldine.

In: Expert Opinion on Drug Safety, Vol. 14, No. 1, 01.01.2015, p. 97-110.

Research output: Contribution to journalReview article

@article{85c96427b06047a482db212edc2410d3,
title = "Class act: Safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma",
abstract = "Introduction: The past decade has seen the development and widespread use of tyrosine kinase inhibitors (TKIs) targeting a mutated EGFR (mEGFR) for the treatment of metastatic NSCLC. We discuss the main properties of the TKIs currently recommended for the treatment of mEGFR NSCLC: gefitinib, erlotinib and afatinib.Areas covered: The mechanism of action, pharmacodynamics and pharmacokinetics of these drugs, with emphasis on the historical context of their preclinical and clinical development, will be covered, including potential resistance mechanisms to these first-generation TKIs that has driven the trial design for second and third generations of EGFR inhibitors. Six Phase III clinical trials comparing these three TKIs with cisplatin-based chemotherapy upfront for mEGFR NSCLC provide the basis for the comparative safety and toxicity analysis between these agents. Class-related toxicity of these EGFR inhibitors, including life-threatening effects, will be discussed.Expert opinion: Toxicity and safety analysis from the Phase III trials of these agents in mEGFR populations suggests that afatinib has more frequent and severe side effects. Given that an efficacy advantage has not yet been demonstrated for afatinib over erlotinib and gefitinib, the consistent class toxicity profile of these agents means that gefitinib and erlotinib are a safer first-line treatment recommendation.",
keywords = "Afatinib, Clinical trial, Erlotinib, Gefitinib, Mutated EGFR, Safety, Toxicity, Tyrosine kinase inhibitor",
author = "Mauricio Burotto and Ali, {Syed Abbas} and {O'sullivan Coyne}, Geraldine",
year = "2015",
month = "1",
day = "1",
doi = "10.1517/14740338.2014.973400",
language = "English (US)",
volume = "14",
pages = "97--110",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Class act

T2 - Safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma

AU - Burotto, Mauricio

AU - Ali, Syed Abbas

AU - O'sullivan Coyne, Geraldine

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction: The past decade has seen the development and widespread use of tyrosine kinase inhibitors (TKIs) targeting a mutated EGFR (mEGFR) for the treatment of metastatic NSCLC. We discuss the main properties of the TKIs currently recommended for the treatment of mEGFR NSCLC: gefitinib, erlotinib and afatinib.Areas covered: The mechanism of action, pharmacodynamics and pharmacokinetics of these drugs, with emphasis on the historical context of their preclinical and clinical development, will be covered, including potential resistance mechanisms to these first-generation TKIs that has driven the trial design for second and third generations of EGFR inhibitors. Six Phase III clinical trials comparing these three TKIs with cisplatin-based chemotherapy upfront for mEGFR NSCLC provide the basis for the comparative safety and toxicity analysis between these agents. Class-related toxicity of these EGFR inhibitors, including life-threatening effects, will be discussed.Expert opinion: Toxicity and safety analysis from the Phase III trials of these agents in mEGFR populations suggests that afatinib has more frequent and severe side effects. Given that an efficacy advantage has not yet been demonstrated for afatinib over erlotinib and gefitinib, the consistent class toxicity profile of these agents means that gefitinib and erlotinib are a safer first-line treatment recommendation.

AB - Introduction: The past decade has seen the development and widespread use of tyrosine kinase inhibitors (TKIs) targeting a mutated EGFR (mEGFR) for the treatment of metastatic NSCLC. We discuss the main properties of the TKIs currently recommended for the treatment of mEGFR NSCLC: gefitinib, erlotinib and afatinib.Areas covered: The mechanism of action, pharmacodynamics and pharmacokinetics of these drugs, with emphasis on the historical context of their preclinical and clinical development, will be covered, including potential resistance mechanisms to these first-generation TKIs that has driven the trial design for second and third generations of EGFR inhibitors. Six Phase III clinical trials comparing these three TKIs with cisplatin-based chemotherapy upfront for mEGFR NSCLC provide the basis for the comparative safety and toxicity analysis between these agents. Class-related toxicity of these EGFR inhibitors, including life-threatening effects, will be discussed.Expert opinion: Toxicity and safety analysis from the Phase III trials of these agents in mEGFR populations suggests that afatinib has more frequent and severe side effects. Given that an efficacy advantage has not yet been demonstrated for afatinib over erlotinib and gefitinib, the consistent class toxicity profile of these agents means that gefitinib and erlotinib are a safer first-line treatment recommendation.

KW - Afatinib

KW - Clinical trial

KW - Erlotinib

KW - Gefitinib

KW - Mutated EGFR

KW - Safety

KW - Toxicity

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84918584616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918584616&partnerID=8YFLogxK

U2 - 10.1517/14740338.2014.973400

DO - 10.1517/14740338.2014.973400

M3 - Review article

C2 - 25345687

AN - SCOPUS:84918584616

VL - 14

SP - 97

EP - 110

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 1

ER -